tert-butyl 2-(diethoxyphosphoryl)-3-(1,3-thiazol-4-yl)propanoate | 866028-88-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: tert-butyl 2-(diethoxyphosphoryl)-3-(1,3-thiazol-4-yl)propanoate
• 英文别名: tert-Butyl 2-(diethoxyphosphoryl)-3-(1,3-thiazol-4-yl)propanoate；tert-butyl 2-diethoxyphosphoryl-3-(1,3-thiazol-4-yl)propanoate
• CAS: 866028-88-8
• 化学式: C₁₄H₂₄NO₅PS
• 分子量: 349.388
• InChiKey: UVKSQZYCJDKDHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  22
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  103
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  tert-butyl 2-(diethoxyphosphoryl)-3-(1,3-thiazol-4-yl)propanoate 在 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 194.92h， 生成 3-(3'H,8H-spiro[8-azabicyclo[3.2.1]octane-3,1'-[2]benzofuran]-8-yl)-2-(1,3-thiazol-4-ylmethyl)propanoic acid trifluoroacetate
  参考文献：
  名称：

  WO2006/134486

  摘要：

  公开号：
• 作为产物：
  描述：

  4-(溴甲基)-1,3-噻唑 、 二乙基膦酰基乙酸叔丁酯 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 0.75h， 生成 tert-butyl 2-(diethoxyphosphoryl)-3-(1,3-thiazol-4-yl)propanoate
  参考文献：
  名称：

  WO2006/134486

  摘要：

  公开号：

文献信息

• Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists
  申请人：Hashizume Yoshinobu

  公开号：US20050277659A1

  公开（公告）日：2005-12-15

  This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 independently represent a hydrogen atom or the like; R 3 represents an aryl group having from 6 to 10 ring atoms or the like; X represents an oxygen atom, or the like; Y represents an oxygen atom or the like; and n represents an integer 0, 1 or 2. These compounds have ORL 1 -receptor antagonist activity; and therefore, are useful to treat diseases or conditions such as pain, various CNS diseases etc.

  本发明提供了式（I）的化合物：或其药学上可接受的酯，或其药学上可接受的盐，其中R1和R2分别独立地表示氢原子或类似物；R3表示具有6至10个环原子或类似物的芳基基团；X表示氧原子或类似物；Y表示氧原子或类似物；n表示整数0、1或2。这些化合物具有ORL1受体拮抗活性；因此，它们可用于治疗疾病或病症，例如疼痛，各种中枢神经系统疾病等。
• Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidino Propanamide Compounds as Orl-1-Receptor Antagonists
  申请人：Hashizume Yoshinobu

  公开号：US20080200490A1

  公开（公告）日：2008-08-21

  This invention provides the compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 independently represent hydrogen or the like; R 3 and R 4 independently represents hydrogen or the like; R 5 represents aryl or the like; —X—Y— represents —CH 2 O— or the like; and n represents 0, 1 or 2. These compounds have ORL1-receptor antagonist activity; and therefore, are useful to treat diseases or conditions such as pain, various CNS diseases etc.

  本发明提供了式（I）的化合物或其药学上可接受的盐，其中R1和R2独立地代表氢或类似物；R3和R4独立地代表氢或类似物；R5代表芳基或类似物；—X—Y—代表—CH2O—或类似物；n代表0、1或2。这些化合物具有ORL1受体拮抗活性；因此，它们可用于治疗疾病或情况，如疼痛、各种中枢神经系统疾病等。
• Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidinopropanoic Acid Compounds as Orl-1-Receptor Antagonists
  申请人：Hashizume Yoshinobu

  公开号：US20080207665A1

  公开（公告）日：2008-08-28

  This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester or salt thereof, wherein R 1 and R 2 independently represent hydrogen or the like; R 3 represents aryl or the like; —X—Y— represents —CH 2 O— or the like, and n represents 0, 1 or 2. These compounds have ORL1-receptor antagonist activity; and therefore, are useful to treat diseases or conditions such as pain, various CNS diseases etc.

  本发明提供了以下化合物的配方(I)：或其药学上可接受的酯或盐，其中R1和R2独立地代表氢或类似物；R3代表芳基或类似物；-X-Y-代表-CH2O-或类似物，n代表0、1或2。这些化合物具有ORL1受体拮抗活性；因此，它们可用于治疗疼痛、各种中枢神经系统疾病等疾病或病况。
• Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonists
  申请人：Hashizume Yoshinobu

  公开号：US20070197500A1

  公开（公告）日：2007-08-23

  This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 independently represent a hydrogen atom or the like; R 3 represents a hydrogen atom, or the like; R 4 represents a hydrogen atom or the like; (formula II) represents one of the following or the like; R 5 represents an aryl group having from 6 to 10 ring atoms or the like; X represents an oxygen atom, or the like; Y represents an oxygen atom or the like and n represents an integer 0, 1 or 2. These compounds have ORL1-receptor antagonist activity; and therefore, are useful to treat diseases or conditions such as pain, various CNS diseases etc.

  本发明提供了以下化合物的公式(I)、其药学上可接受的酯或其药学上可接受的盐，其中R1和R2独立地表示氢原子或类似物；R3表示氢原子或类似物；R4表示氢原子或类似物；(公式II)代表以下之一或类似物；R5表示具有6至10个环原子的芳基基团或类似物；X表示氧原子或类似物；Y表示氧原子或类似物，n表示整数0、1或2。这些化合物具有ORL1受体拮抗活性；因此，它们对于治疗疾病或症状，如疼痛、各种中枢神经系统疾病等非常有用。
• Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists
  申请人：Pfizer Inc.

  公开号：US07354925B2

  公开（公告）日：2008-04-08

  This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 independently represent a hydrogen atom or the like; R3 represents a hydrogen atom, or the like; R4 represents a hydrogen atom or the like; represents one of the following or the like; R5 represents an aryl group having from 6 to 10 ring atoms or the like; X represents an oxygen atom, or the like; Y represents an oxygen atom or the like and n represents an integer 0, 1 or 2. These compounds have ORL1-receptor antagonist activity; and therefore, are useful to treat diseases or conditions such as pain, various CNS diseases etc.

  本发明提供了式(I)的化合物：或其药物可接受的酯，或其药物可接受的盐，其中R1和R2独立表示氢原子或类似物；R3表示氢原子或类似物；R4表示氢原子或类似物；表示以下之一或类似物；R5表示具有6至10个环原子的芳基基团或类似物；X表示氧原子或类似物；Y表示氧原子或类似物，n表示整数0、1或2。这些化合物具有ORL1受体拮抗活性；因此，它们可用于治疗疼痛、各种中枢神经系统疾病等疾病或症状。